-
Article
Open Access3D engineered scaffold for large-scale Vigil immunotherapy production
Previously, we reported successful cellular expansion of a murine colorectal carcinoma cell line (CT-26) using a three-dimensional (3D) engineered extracellular matrix (EECM) fibrillar scaffold structure. CCL-...
-
Article
Open AccessAuthor Correction: ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer
-
Article
Open AccessENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer
Broadened use of predictive molecular and phenotypic profiling amongst oncologists has facilitated optimal integration of targeted- and immuno-therapeutics into clinical care. However, the use of predictive im...
-
Article
Open AccessNetwork based analysis identifies TP53m-BRCA1/2wt-homologous recombination proficient (HRP) population with enhanced susceptibility to Vigil immunotherapy
Thus far immunotherapy has had limited impact on ovarian cancer. Vigil (a novel DNA-based multifunctional immune-therapeutic) has shown clinical benefit to prolong relapse-free survival (RFS) and overall survi...
-
Article
Proof of principle study of sequential combination atezolizumab and Vigil in relapsed ovarian cancer
Vigil® is a personalized vaccine that enhances tumor neoantigen expression. We investigated for the first time safety and efficacy of Vigil in combination with atezolizumab in relapsed ovarian cancer (OC) pati...
-
Chapter
Cost Effective High Density Mammalian Cell Culture
High density mammalian cell culture offers superior and unique cost savings opportunities over other culture methods. Significant savings in both capital and operating costs are possible and must be achieved f...
